IP Library Granted Patent US 10,017,742
Granted Patent B2
US 10,017,742 · App. 14/539,158 · Granted Jul 10, 2018

Process for the preparation of disinfected human cell suspensions

Inventors: Krasimira Aleksandrova (Hannover, DE); Marc Barthold (Hannover, DE); Lubomir Arseniev (Hannover, DE); Carsten Griesel (Ladenburg, DE); Christoph Priesner (Hannover, DE)
Assignee: Cytonet GmbH & Co. KG
C12N5/067A01N1/0215C12N2501/70C12N2509/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,017,742
App. No.
14/539,158
Granted
Jul 10, 2018
Kind
B2
Abstract

In a process for preparing disinfected preparations from mammalian tissues, mammalian tissue is perfused at one step with an enzyme-free liquid antibiotic composition that includes at least one antibiotic and is contained in at least one perfusion buffer. In a step occurring after such one step, enzymatic antibiotic-free treatment of the tissue is carried out to obtain a single-cell suspension. In another step disinfected preparations are obtained.

Claims (25)

1. A process for the preparation of disinfected preparations from isolated mammalian tissues or isolated organs, comprising the following process steps:

a) perfusing the isolated mammalian tissue or isolated organ with an enzyme-free liquid antibiotic composition that comprises at least one antibiotic selected from the group consisting of non-penicillin of β-lactam antibiotics, aminoglycosides, glycopeptide antibiotics, and polypeptide antibiotics, and is contained in at least one perfusion buffer,

b) carrying out an enzymatic, antibiotic-free treatment of the isolated mammalian tissue or the isolated organ to obtain a single-cell suspension, wherein the enzyme used for the enzymatic treatment are able to dissolve cell/cell contacts and cell/extracellular matrix contacts, and

c) obtaining disinfected single-cell suspension preparations,

wherein the enzymatic treatment according to step (b) takes place after step (a).

2. The process according to claim 1 , wherein the tissue is liver tissue and the organ is liver.

3. The process according to claim 1 , wherein the enzymatic treatment comprises a treatment with at least one of collagenase and proteinase.

4. The process according to claim 1 , wherein perfusion time in process step a) is 30 to 120 min and temperature of the liquid antibiotic composition is increased during the perfusion.

5. The process according to claim 1 , wherein the enzyme-free liquid antibiotic composition is contained in at least two perfusion buffers, at least one of the perfusion buffers being an EGTA- or EDTA-containing phosphate/HEPES buffer and at least one other of the buffers being a phosphate/HEPES buffer.

6. The process according to claim 1 , wherein the surfaces of the tissue is rinsed with a liquid antibiotic composition prior to process step a).

7. The process according to claim 1 , wherein at least one washing step using an antibiotic-free washing buffer is carried out after process step b).

8. The process according to claim 1 , further comprising:

washing the obtained disinfected single-cell suspension preparations with an antibiotic-free washing buffer to obtain washed disinfected single-cell suspension preparations;

wherein said washing is adapted to either one of reduce or eliminate said antibiotic from said disinfected single-cell suspension so as not to have a negative effect on a microbiological sterility test.

9. The process according to claim 1 , wherein the enzyme-free liquid antibiotic composition comprises Meropenem and Vancomycin.

10. The process according to claim 1 , wherein the enzyme used for enzymatic treatment is a mixture of collagenase and proteinase in a ratio of enzymatic activities of 1 unit of collagenase to 40 to 60 units of proteinase.

11. A process for the preparation of disinfected preparations from isolated mammalian tissues or isolated organs, comprising the following process steps:

a) perfusing the isolated mammalian tissue or isolated organ with an enzyme-free liquid antibiotic composition that comprises at least one antibiotic selected from the group consisting of non-penicillin of β-lactam antibiotics, aminoglycosides, glycopeptide antibiotics, and polypeptide antibiotics, and is contained in at least one perfusion buffer,

b) carrying out an enzymatic, antibiotic-free treatment of the isolated mammalian tissue or the isolated organ to obtain a single-cell suspension, wherein the enzyme used for the enzymatic treatment are able to dissolve cell/cell contacts and cell/extracellular matrix contacts, and

c) obtaining disinfected single-cell suspension preparations,

wherein:

(i) the enzymatic treatment according to step (b) takes place after step (a), and

(ii) the enzymatic treatment comprises a treatment with at least one of collagenase and proteinase, and/or

(iii) perfusion time in process step a) is 30 to 120 min and temperature of the liquid antibiotic composition is increased during the perfusion, and/or

(iv) the enzyme-free liquid antibiotic composition is contained in at least two perfusion buffers, at least one of the perfusion buffers being an EGTA- or EDTA-containing phosphate/HEPES buffer and at least one other of the buffers being a phosphate/HEPES buffer.

Assignments (3)
CHANGE OF NAME Recorded Jan 9, 2024
From: PROMETHERA THERAPEUTICS SA
To: CELLAÏON SA
Reel/Frame 066064/0328 →
NUNC PRO TUNC ASSIGNMENT Recorded Mar 24, 2021
From: PROMETHERA BIOSCIENCES SA
To: PROMETHERA THERAPEUTICS SA
Reel/Frame 055707/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2016
From: CYTONET GMBH & CO. KG.
To: PROMETHERA BIOSCIENCES SA
Reel/Frame 040436/0376 →
Priority Claims (1)
DE 10 2010 034 330 · Aug 14, 2010 · national
Continuity (2)
Continuation 13816909
Related Publication 20150072428A1 · Mar 12, 2015